Table 4.
Combined results of meta-analysis showing effect of niacin, fibrate, and cholesteryl ester transfer protein (CETP) inhibitors on risk of all cause mortality, coronary heart disease mortality, non-fatal myocardial infarction, and stroke
| Events by drug class | No of events/Total | Odds ratio (Mantel-Haenszel random (95% CI) | P value | |
|---|---|---|---|---|
| Intervention | Placebo | |||
| Niacin | ||||
| All cause mortality: | ||||
| All trials | 1194/17 030 | 1486/18 271 | 1.03 (0.92 to 1.15) | 0.59 |
| Non-statin trials | 299/1659 | 669/3332 | 0.86 (0.65 to 1.1.4) | 0.29 |
| Statin trials | 895/15 371 | 817/14 939 | 1.10 (1.00 to 1.21) | 0.06 |
| Coronary heart disease mortality: | ||||
| All trials | 565/16 795 | 852/18 034 | 0.93 (0.76 to 1.12) | 0.44 |
| Non-statin trials | 2225/1563 | 527/3231 | 0.75 (0.48 to 1.18) | 0.21 |
| Statin trials | 340/15 232 | 325/14 803 | 1.05 (0.90 to 1.22) | 0.57 |
| Non-fatal myocardial infarction: | ||||
| All trials | 645/17030 | 921/18271 | 0.85 (0.72 to 1.01) | 0.07 |
| Non-statin trials | 136/1659 | 399/3332 | 0.69 (0.56 to 0.85) | 0.0004 |
| Statin trials | 509/15371 | 527/14939 | 0.96 (0.85 to 1.09) | 0.52 |
| Stroke: | ||||
| All trials | 620/16 788 | 797/18 020 | 0.96 (0.75 to 1.22) | 0.72 |
| Non-statin trials | 92/1517 | 278/3189 | 0.78 (0.61 to 1.00) | 0.05 |
| Statin trials | 528/15 319 | 519/14 883 | 1.10 (0.70 to 1.74) | 0.68 |
| Fibrates | ||||
| All cause mortality: | ||||
| All trials | 1763/22 140 | 2123/23 795 | 0.98 (0.89 to 1.08) | 0.66 |
| Non-statin trials | 1204/14 480 | 1579/16 142 | 0.96 (0.86 to 1.09) | 0.55 |
| Statin trials | 559/7660 | 544/7653 | 1.01 (0.83 to 1.24) | 0.89 |
| Coronary heart disease mortality: | ||||
| All trials | 704/21 886 | 1032/23 536 | 0.92 (0.81 to 1.04) | 0.19 |
| Non-statin trials | 582/14 226 | 925/15 883 | 0.88 (0.78 to 1.00) | 0.05 |
| Statin trials | 122/7660 | 107/7653 | 1.14 (0.88 to 1.49) | 0.32 |
| Non-fatal myocardial infarction: | ||||
| All trials | 1104/21 896 | 1574/23 549 | 0.80 (0.74 to 0.87) | <0.001 |
| Non-statin trials | 773/14 236 | 1181/15 896 | 0.78 (0.71 to 0.86) | <0.001 |
| Statin trials | 331/7660 | 393/7653 | 0.83 (0.69 to 1.01) | 0.07 |
| Stroke: | ||||
| All trials | 610/20 784 | 772/22 404 | 1.01 (0.90 to 1.13) | 0.84 |
| Non-statin trials | 401/13 124 | 549/14 751 | 1.06 (0.91 to 1.23) | 0.48 |
| Statin trials | 209/7660 | 223/7653 | 0.94 (0.77 to 1.13) | 0.49 |
| CETP inhibitors | ||||
| All trials: | ||||
| All cause mortality | 340/18 003 | 307/18 008 | 1.16 (0.93 to 1.44) | 0.19 |
| Coronary heart disease mortality | 163/18 003 | 163/18 008 | 1.00 (0.80 to 1.24) | 0.99 |
| Non-fatal myocardial infarction | 582/18 003 | 553/18 008 | 1.05 (0.93 to 1.18) | 0.41 |
| Stroke | 143/18 003 | 127/18 008 | 1.14 (0.90 to 1.45) | 0.29 |